See the Skin Health Overview article


Sunlight exposure is the primary source of vitamin D for most people. Solar ultraviolet-B radiation (UVB; wavelengths of 290 to 315 nanometers) stimulates the production of vitamin D3 from 7-dehydrocholesterol (7-DHC) in the epidermis of the skin (see Production in Skin) (1). Hence, vitamin D is actually more like a hormone than a vitamin, a substance that is required from the diet. Vitamin D3 enters the circulation and is transported to the liver, where it is hydroxylated to form 25-hydroxyvitamin D3 (calcidiol; the major circulating form of vitamin D). In the kidneys, the 25-hydroxyvitamin D3-1-hydroxylase enzyme catalyzes a second hydroxylation of 25-hydroxyvitamin D, resulting in the formation of 1,25-dihydroxyvitamin D3 (calcitriol, 1α,25-dihydroxyvitamin D] — the most potent form of vitamin D (2). Most of the physiological effects of vitamin D in the body are related to the activity of 1,25-dihydroxyvitamin D3; see the article on Vitamin D. Keratinocytes in the epidermis possess hydroxylase enzymes that locally convert vitamin D to 1,25-dihydroxyvitamin D3 (3-5), the form that regulates epidermal proliferation and differentiation (see Metabolism in keratinocytes).

Topical application

Calcitriol (1,25-dihydroxyvitamin D3) has been used topically to treat certain skin conditions, including psoriasis, a skin condition that involves a hyperproliferation of keratinocytes. Several studies found that topical use of calcitriol (3 μg/g) ointment is safe and may be an effective treatment for plaque-type psoriasis (6-8). The vitamin D analog called calcipotriene or calcipotriol has also been used as a treatment for chronic plaque psoriasis, either alone or in combination with corticosteroids (9, 10).



Covering exposed skin or using sunscreen whenever outside are risk factors for vitamin D deficiency. The consequences of vitamin D deficiency primarily concern bone health. In vitamin D deficiency, calcium absorption cannot be increased enough to satisfy the body’s calcium needs. Consequently, parathyroid hormone (PTH) production by the parathyroid glands is increased and calcium is mobilized from bone to maintain normal serum calcium levels (see the article on Vitamin D).

Production in Skin

Upon exposure to UVB radiation, previtamin D3 is synthesized from 7-DHC in the skin, primarily in keratinocytes of the stratum basale and stratum spinosum layers of the epidermis. Previtamin D3 isomerizes to form vitamin D3 (cholecalciferol), which is subsequently transported into the circulation via a binding protein (11). Previtamin D3 can also isomerize to form the photoproducts, tachysterol3 or lumisterol3; the reaction that forms this latter compound is reversible. Both isomers are biologically inactive (i.e., do not enhance intestinal calcium absorption), do not significantly enter the circulation, apparently serve as a mechanism to prevent vitamin D toxicity from prolonged sun exposure, and are probably sloughed off when skin cells are naturally shed (12). Upon exposure to sunlight, vitamin D3 can also be degraded to other photoproducts, including 5,6-trans-vitamin D3, suprasterol I, and suprasterol II (13). Like the active form of vitamin D, some of the mentioned photoproducts may regulate epidermal proliferation and differentiation (14), but elucidation of their biological relevance will require further study.

Numerous variables affect skin synthesis of vitamin D, including latitude, season, time of day, degree of skin pigmentation, age, amount of skin exposed, and sunscreen use. Latitude, season, and time of day create the solar zenith angle, which determines the intensity of sunlight (15). People living in higher latitudes are more at risk for vitamin D deficiency compared to those living in more equatorial latitudes because the sunlight intensity is lower. For those residing in temperate latitudes, time of year influences the ability to generate previtamin D3 in skin. In latitudes around 40 degrees north or 40 degrees south (Boston is 42 degrees north), there is insufficient UVB radiation available for vitamin D synthesis from November to early March. Ten degrees farther north (Edmonton, Canada) or south the “vitamin D winter” extends from October to April (16). Time of day also influences the ability to generate vitamin D in skin, with midday solar radiation being the most intense. Melanin, the dark pigment in skin, competes with 7-DHC for the absorption of UV light and thus acts as a natural sunscreen, reducing the effectiveness of vitamin D production in skin. Therefore, individuals with dark-colored skin require more time (up to ten times as long) to synthesize the same amount of previtamin D3 in skin as those with fair skin (12, 17).

According to Dr. Michael Holick, sensible sun exposure, i.e., exposing bare arms and legs to midday sun (between 10 am and 3 pm) for 5-30 minutes twice weekly, may be sufficient to meet vitamin D requirements (18); however, as mentioned above, season, latitude, and skin pigmentation all affect vitamin D synthesis in skin. Other factors influence the ability to produce vitamin D in skin. For example, aging reduces the capacity to synthesize vitamin D in skin since older adults have lower skin concentrations of the vitamin D precursor, 7-DHC, compared to younger individuals (19). Moreover, use of sunscreen effectively blocks UVB absorption and therefore vitamin D synthesis in skin: application of sunscreen with a sun protection factor (SPF) of 8 reduces production of vitamin D in skin by more than 95% (20). Thus, several factors can have a substantial impact on body vitamin D levels through affecting the production of the vitamin in skin.

Metabolism in Keratinocytes

Keratinocytes of the epidermis possess the enzymes needed to convert vitamin D to its active form, 1,25-dihydroxyvitamin D3 (3-5), as well as the vitamin D receptor (VDR), a transcription factor that regulates gene expression. The active form of vitamin D functions as a steroid hormone. Upon entering the nucleus, 1,25-dihydroxyvitamin D3 associates with the VDR, which heterodimerizes with the retinoic acid X receptor (RXR). This complex binds small sequences of DNA known as vitamin D response elements (VDREs); the binding initiates a cascade of molecular interactions that modulate the transcription of certain genes (21, 22). In this manner, 1,25-dihydroxyvitamin D3 functions locally to regulate the proliferation and differentiation of keratinocytes.

Biological Activities in Skin

Control of epidermal proliferation and differentiation

The bottom or basal layer of the epidermis, called the stratum basale, consists of a layer of round, undifferentiated keratinocytes that is supported by the underlying dermis. Cells in the stratum basale are constantly proliferating in order to produce new cells that will comprise the upper epidermal layers (23, 24). Once a keratinocyte leaves the stratum basale, it begins the process of differentiation (specialization of cells for specific functions) known as keratinization and also undergoes cornification, a process in which keratinocytes become corneocytes (24; see the article, Micronutrients and Skin Health). Thus, new cells from the stratum basale replace the outer layer of skin cells that is shed over time.

Along with various coregulators, 1,25-dihydroxyvitamin D3 and its receptor, the VDR, regulate the abovementioned processes that replenish skin. In general, vitamin D inhibits the expression of genes responsible for keratinocyte proliferation and induces the expression of genes responsible for keratinocyte differentiation (25). In addition to its steroid hormone actions, vitamin D regulates biochemical steps that result in a cellular influx of calcium, which is important in cell differentiation (26). The processes of epidermal proliferation and differentiation are essential for normal cell growth, wound healing, and maintaining the barrier function of skin. Because uncontrolled proliferation of cells with certain mutations may lead to cancer, vitamin D may protect against certain cancers (see the article on Vitamin D).

Other activities

In skin, the vitamin D receptor (VDR) appears to have other roles that are independent of its association with 1,25-dihydroxyvitamin D3. For instance, the VDR is important in regulating the growth cycle of mature hair follicles (27, 28). Certain mutations in the VDR lead to misregulated gene expression resulting in aberrant hair follicle cycling and alopecia (hair loss) in mice (28, 29) and in humans (30). The VDR also functions as a tumor suppressor in skin (31). The VDR is one of several factors that control these two diverse roles. Moreover, 1,25-dihydroxyvitamin D3 is a potent immune modulator in skin; for general information about vitamin D and immunity, see the article on Nutrition and Immunity.

Functions in Healthy Skin


Photodamage refers to skin damage induced by ultraviolet (UV) light. Depending on the dose, UV light can lead to DNA damage, inflammatory responses, skin cell apoptosis (programmed cell death), skin aging, and skin cancer. Some studies, mainly in vitro (cell culture) studies (32-35) and mouse studies where 1,25-dihydroxyvitamin D3 was topically applied to skin before or immediately following irradiation (32, 36, 37), have found that vitamin D exhibits photoprotective effects. Documented effects in skin cells include decreased DNA damage, reduced apoptosis, increased cell survival, and decreased erythema. The mechanisms for such effects are not known, but one mouse study found that 1,25-dihydroxyvitamin D3 induced expression of metallothionein (a protein that protects against free radicals and oxidative damage) in the stratum basale (32). It has also been postulated that non-genomic actions of vitamin D contribute to the photoprotection (38); such effects of vitamin D involve cell-signaling cascades that open calcium channels (39).

Wound healing

1,25-dihydroxyvitamin D3 regulates the expression of cathelicidin (LL-37/hCAP18) (40, 41), an antimicrobial protein that appears to mediate innate immunity in skin by promoting wound healing and tissue repair. One human study found that cathelicidin expression is upregulated during early stages of normal wound healing (42). Other studies have shown that cathelicidin modulates inflammation in skin (43), induces angiogenesis (44), and improves reepithelialization (the process of restoring the epidermal barrier to re-establish a functional barrier that protects underlying cells from environmental exposures) (42). The active form of vitamin D and its analogs have been shown to upregulate cathelicidin expression in cultured keratinocytes (41, 45). However, more research is needed to determine the role of vitamin D in wound healing and epidermal barrier function, and whether oral vitamin D supplementation or topical treatment with vitamin D analogs is helpful in healing surgical wounds.


Sun exposure is the primary source of vitamin D for most people. Upon exposure to ultraviolet-B radiation, previtamin D3 is synthesized in keratinocytes of the epidermis. Previtamin D3 isomerizes to form vitamin D3 (cholecalciferol), which is subsequently transported into the circulation or metabolized by keratinocytes. Keratinocytes can locally convert previtamin D3 to the active form, 1,25-dihydroxyvitamin D3. 1,25-dihydroxyvitamin D3 and its receptor, the VDR, have several biological functions in skin, including regulating the proliferation and differentiation of keratinocytes, hair follicle cycling, and tumor suppression. Some cell culture and rodent studies have shown that 1,25-dihydroxyvitamin D3 exhibits photoprotective effects. Moreover, vitamin D is known to modulate inflammation and may be involved in wound healing. However, more research is needed to understand the exact roles of vitamin D and its receptor in the maintenance of healthy skin.

Authors and Reviewers

Written in November 2011 by:
Victoria J. Drake, Ph.D.
Linus Pauling Institute
Oregon State University

Reviewed in November 2011 by:
Daniel D. Bikle, M.D., Ph.D.
Professor, Departments of Medicine and Dermatology
The University of California, San Francisco

This article was underwritten, in part, by a grant from Neutrogena Corporation, Los Angeles, California.

Copyright 2011-2024  Linus Pauling Institute


1.  Holick MF. Resurrection of vitamin D deficiency and rickets. J Clin Invest. 2006;116(8):2062-2072.  (PubMed)

2.  Brunette MG, Chan M, Ferriere C, Roberts KD. Site of 1,25(OH)2 vitamin D3 synthesis in the kidney. Nature. 1978;276(5685):287-289.  (PubMed)

3.  Bikle DD, Nemanic MK, Gee E, Elias P. 1,25-Dihydroxyvitamin D3 production by human keratinocytes. Kinetics and regulation. J Clin Invest. 1986;78(2):557-566.  (PubMed)

4.  Bikle DD, Nemanic MK, Whitney JO, Elias PW. Neonatal human foreskin keratinocytes produce 1,25-dihydroxyvitamin D3. Biochemistry. 1986;25(7):1545-1548.  (PubMed)

5.  Lehmann B, Sauter W, Knuschke P, Dressler S, Meurer M. Demonstration of UVB-induced synthesis of 1 alpha,25-dihydroxyvitamin D3 (calcitriol) in human skin by microdialysis. Arch Dermatol Res. 2003;295(1):24-28.  (PubMed)

6.  Abramovits W. Calcitriol 3 microg/g ointment: an effective and safe addition to the armamentarium in topical psoriasis therapy. J Drugs Dermatol. 2009;8(8 Suppl):s17-22.  (PubMed)

7.  Gerritsen MJ, Van De Kerkhof PC, Langner A. Long-term safety of topical calcitriol 3 microg g(-1) ointment. Br J Dermatol. 2001;144 Suppl 58:17-19.  (PubMed)

8.  Rizova E, Corroller M. Topical calcitriol--studies on local tolerance and systemic safety. Br J Dermatol. 2001;144 Suppl 58:3-10.  (PubMed)

9.  Mason AR, Mason J, Cork M, Dooley G, Edwards G. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev. 2009(2):CD005028.  (PubMed)

10.  Murphy G, Reich K. In touch with psoriasis: topical treatments and current guidelines. J Eur Acad Dermatol Venereol. 2011;25 Suppl 4:3-8.  (PubMed)

11.  Holick MF, MacLaughlin JA, Clark MB, et al. Photosynthesis of previtamin D3 in human skin and the physiologic consequences. Science. 1980;210(4466):203-205.  (PubMed)

12.  Holick MF, MacLaughlin JA, Doppelt SH. Regulation of cutaneous previtamin D3 photosynthesis in man: skin pigment is not an essential regulator. Science. 1981;211(4482):590-593.  (PubMed)

13.  Webb AR, DeCosta BR, Holick MF. Sunlight regulates the cutaneous production of vitamin D3 by causing its photodegradation. J Clin Endocrinol Metab. 1989;68(5):882-887.  (PubMed)

14.  Chen TC, Persons KS, Lu Z, Mathieu JS, Holick MF. An evaluation of the biologic activity and vitamin D receptor binding affinity of the photoisomers of vitamin D3 and previtamin D3. J Nutr Biochem. 2000;11(5):267-272.  (PubMed)

15.  Tsiaras WG, Weinstock MA. Factors influencing vitamin D status. Acta Derm Venereol. 2011;91(2):115-124.  (PubMed)

16.  Webb AR, Kline L, Holick MF. Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J Clin Endocrinol Metab. 1988;67(2):373-378.  (PubMed)

17.  Holick MF. Vitamin d: a d-lightful solution for health. J Investig Med. 2011;59(6):872-880.  (PubMed)

18.  Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266-281.  (PubMed)

19.  MacLaughlin J, Holick MF. Aging decreases the capacity of human skin to produce vitamin D3. J Clin Invest. 1985;76(4):1536-1538.  (PubMed)

20.  Matsuoka LY, Ide L, Wortsman J, MacLaughlin JA, Holick MF. Sunscreens suppress cutaneous vitamin D3 synthesis. J Clin Endocrinol Metab. 1987;64(6):1165-1168.  (PubMed)

21.  Jones G, Strugnell SA, DeLuca HF. Current understanding of the molecular actions of vitamin D. Physiol Rev. 1998;78(4):1193-1231.  (PubMed)

22.  Jurutka PW, Whitfield GK, Hsieh JC, Thompson PD, Haussler CA, Haussler MR. Molecular nature of the vitamin D receptor and its role in regulation of gene expression. Rev Endocr Metab Disord. 2001;2(2):203-216.  (PubMed)

23.  Odland GF. Structure of the skin. In: Goldsmith LA, ed. Physiology, biochemistry, and molecular biology of the skin. 2nd ed. New York: Oxford University Press; 1991:3-62.

24.  Freinkel RK, Woodley D. The biology of the skin. New York: Parthenon Pub. Group; 2001.

25.  Bikle DD. Vitamin D metabolism and function in the skin. Mol Cell Endocrinol. 2011;347(1-2):80-89.  (PubMed)

26.  Bikle DD, Pillai S. Vitamin D, calcium, and epidermal differentiation. Endocr Rev. 1993;14(1):3-19.  (PubMed)

27.  Skorija K, Cox M, Sisk JM, et al. Ligand-independent actions of the vitamin D receptor maintain hair follicle homeostasis. Mol Endocrinol. 2005;19(4):855-862.  (PubMed)

28.  Sakai Y, Demay MB. Evaluation of keratinocyte proliferation and differentiation in vitamin D receptor knockout mice. Endocrinology. 2000;141(6):2043-2049.  (PubMed)

29.  Li YC, Pirro AE, Amling M, et al. Targeted ablation of the vitamin D receptor: an animal model of vitamin D-dependent rickets type II with alopecia. Proc Natl Acad Sci U S A. 1997;94(18):9831-9835.  (PubMed)

30.  Malloy PJ, Feldman D. The role of vitamin D receptor mutations in the development of alopecia. Mol Cell Endocrinol. 2011;347(1-2):90-96.  (PubMed)

31.  Bikle DD. Vitamin D and the skin. J Bone Miner Metab. 2010;28(2):117-130.  (PubMed)

32.  Lee J, Youn JI. The photoprotective effect of 1,25-dihydroxyvitamin D3 on ultraviolet light B-induced damage in keratinocyte and its mechanism of action. J Dermatol Sci. 1998;18(1):11-18.  (PubMed)

33.  Wong G, Gupta R, Dixon KM, et al. 1,25-Dihydroxyvitamin D and three low-calcemic analogs decrease UV-induced DNA damage via the rapid response pathway. J Steroid Biochem Mol Biol. 2004;89-90(1-5):567-570.  (PubMed)

34.  De Haes P, Garmyn M, Degreef H, Vantieghem K, Bouillon R, Segaert S. 1,25-Dihydroxyvitamin D3 inhibits ultraviolet B-induced apoptosis, Jun kinase activation, and interleukin-6 production in primary human keratinocytes. J Cell Biochem. 2003;89(4):663-673.  (PubMed)

35.  Dixon KM, Deo SS, Wong G, et al. Skin cancer prevention: a possible role of 1,25dihydroxyvitamin D3 and its analogs. J Steroid Biochem Mol Biol. 2005;97(1-2):137-143.  (PubMed)

36.  Dixon KM, Deo SS, Norman AW, et al. In vivo relevance for photoprotection by the vitamin D rapid response pathway. J Steroid Biochem Mol Biol. 2007;103(3-5):451-456.  (PubMed)

37.  Gupta R, Dixon KM, Deo SS, et al. Photoprotection by 1,25 dihydroxyvitamin D3 is associated with an increase in p53 and a decrease in nitric oxide products. J Invest Dermatol. 2007;127(3):707-715.  (PubMed)

38.  Mason RS, Sequeira VB, Dixon KM, et al. Photoprotection by 1alpha,25-dihydroxyvitamin D and analogs: further studies on mechanisms and implications for UV-damage. J Steroid Biochem Mol Biol. 2010;121(1-2):164-168.  (PubMed)

39.  Revelli A, Massobrio M, Tesarik J. Nongenomic effects of 1alpha,25-dihydroxyvitamin D(3). Trends Endocrinol Metab. 1998;9(10):419-427.  (PubMed)

40.  Wang TT, Nestel FP, Bourdeau V, et al. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol. 2004;173(5):2909-2912.  (PubMed)

41.  Gombart AF, Borregaard N, Koeffler HP. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. Faseb J. 2005;19(9):1067-1077.  (PubMed)

42.  Heilborn JD, Nilsson MF, Kratz G, et al. The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. J Invest Dermatol. 2003;120(3):379-389.  (PubMed)

43.  Frohm M, Agerberth B, Ahangari G, et al. The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders. J Biol Chem. 1997;272(24):15258-15263.  (PubMed)

44.  Koczulla R, von Degenfeld G, Kupatt C, et al. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest. 2003;111(11):1665-1672.  (PubMed)

45.  Weber G, Heilborn JD, Chamorro Jimenez CI, Hammarsjo A, Torma H, Stahle M. Vitamin D induces the antimicrobial protein hCAP18 in human skin. J Invest Dermatol. 2005;124(5):1080-1082.  (PubMed)